Barriers to Treatment Access for Chagas Disease in Mexico

PLoS Neglected Tropical Diseases

Volumn 7, Issue 10, 2013, Pages

  Manne, Jennifer M ^a   Snively, Callae S ^a   Ramsey, Janine M ^b   Salgado, Marco Ocampo ^c   Bärnighausen, Till ^a   Reich, Michael R ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^c Secretariat of Health Morelos State   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; NIFURTIMOX;

ARTICLE; CHAGAS DISEASE; HEALTH CARE ACCESS; HEALTH CARE FINANCING; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; MEXICO; PARASITE PREVALENCE; PERSUASIVE COMMUNICATION; PRACTICE GUIDELINE; SEMI STRUCTURED INTERVIEW; SOCIAL INSURANCE; TRYPANOSOMA CRUZI;

ANTIPROTOZOAL AGENTS; CHAGAS DISEASE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERVIEWS AS TOPIC; MEXICO;

EID: 84887305227     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002488     Document Type: Article

References (56)

1. Mathers CD, Ezzati M, Lopez AD, (2007) Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoS Negl Trop Dis 1: e114.
2. Tarleton RL, Reithinger R, Urbina JA, Kitron U, Gurtler RE, (2007) The challenges of Chagas Disease- grim outlook or glimmer of hope. PLoS Med 4: e332.
3. Lee BY, Bacon KM, Bottazzi ME, Hotez PJ, (2013) Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis 13: 342-348.
4. World Health Organization (2002) Control of Chagas Disease: Second report of the WHO Expert Committee. Geneva: World Health Organization.
5. Ribeiro I, Sevcsik AM, Alves F, Diap G, Don R, et al. (2009) New, improved treatments for chagas disease: from the R&D pipeline to the patients. PLoS Negl Trop Dis 3: e484.
6. Pan American Health Organization (2006) Estimacion cuantitativa de la enfermedad de Chagas en las Americas. Montevideo, Uruguay: WHO Department of Control of Neglected Tropical Diseases.
7. Roberts MJ, Reich MR (2011) Pharmaceutical Reform: A Guide to Improving Performance and Equity. Washington, DC: The World Bank.
8. Hoff R, Teixeira RS, Carvalho JS, Mott KE, (1978) Trypanosoma cruzi in the cerebrospinal fluid during the acute stage of Chagas' disease. N Engl J Med 298: 604-606.
9. Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, et al. (2007) Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 298: 2171-2181.
10. Comisión Nacional de Protección Social en Salud (2011) Familias y Beneficiarios por Localidad al Segundo Semestre 2011. Comisión Nacional de Protección Social en Salud.
11. Lescure FX, Le Loup G, Freilij H, Develoux M, Paris L, et al. (2010) Chagas disease: changes in knowledge and management. Lancet Infect Dis 10: 556-570.
12. World Health Organization (2007) WHO Consultation on International Biological Reference Preparations for Chagas Diagnostic Tests. Geneva, Switzerland: World Health Organization,.
13. World Health Assembly (2010) Chagas disease: control and elimination. World Health Assembly,.
14. Carlier Y, Torrico F, Sosa-Estani S, Russomando G, Luquetti A, et al. (2011) Congenital Chagas disease: recommendations for diagnosis, treatment and control of newborns, siblings and pregnant women. PLoS Negl Trop Dis 5: e1250.
15. de Andrade ALZF, de Oliveira RM, Almeida Silva S, Luguetti A, et al. (1996) Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet pp. 348.
16. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, et al. (2006) Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 144: 724-734.
17. Rassi A Jr, Rassi A, Marin-Neto JA, (2010) Chagas disease. Lancet 375: 1388-1402.
18. Bern C, (2011) Antitrypanosomal therapy for chronic Chagas' disease. N Engl J Med 364: 2527-2534.
19. Sosa-Estani S, Viotti R, Segura EL, (2009) Therapy, diagnosis and prognosis of chronic Chagas disease: insight gained in Argentina. Mem Inst Oswaldo Cruz 104 Suppl 1: 167-180.
20. Yun O, Lima MA, Ellman T, Chambi W, Castillo S, et al. (2009) Feasibility, drug safety, and effectiveness of etiological treatment programs for chagas disease in honduras, guatemala, and bolivia: 10-year experience of medecins sans frontieres. PLoS Negl Trop Dis 3: e488.
21. Marin-Neto JA, Rassi A Jr, Avezum A Jr, Mattos AC, Rassi A, et al. (2009) The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz 104 Suppl 1: 319-324.
22. National Institutes of Health (2009) BENEFIT: Evaluation of the Use of Antiparasitic Drug (Benznidazole) in the Treatment of Chronic Chagas Disease. Available: http://clinicaltrials.gov/show/NCT00123916. Accessed 16 September 2013.
23. Manne J, Snively CS, Levy MZ, Reich MR, (2012) Supply chain problems for Chagas disease treatment. Lancet Infect Dis 12: 173-175.
24. Medecins Sans Frontieres (2011) Briefing Document: Shortage of Benznidazole Leaves Thousands of Chagas Patients Without Treatment. Medecins Sans Frontieres.
25. World Pharma News (2011) Bayer extends support to fight Chagas disease. Available: http://press.healthcare.bayer.com/en/press/auth/news-details-page.php/14107/2011-0114. Accessed 16 September 2013.
26. Instituto Nacional de Estadistica y Geografia (INEGI) (2010) Censo de Poblacion y Vivienda 2010. Mexico.
27. Frenk J, Gonzalez-Pier E, Gomez-Dantes O, Lezana MA, Knaul FM, (2006) Comprehensive reform to improve health system performance in Mexico. Lancet 368: 1524-1534.
28. Comision Nacional de Proteccion Social en Salud (2011) Catalogo Universal de Servicios de Salud In: Seguro Popular, editor: Secretaria de Salud- Estados Unidos Mexicanos.
29. Chertorivski S (2011) Detras esta la gente. El Universal. Available: http://www.eluniversal.com.mx/editoriales/53752.html. Accessed 16 September 2013.
30. Aday LA, Andersen R, (1974) A framework for the study of access to medical care. Health Serv Res 9: 208-220.
31. Hanson K, Random MK, Oliveira-Cruz V, Mills A, (2003) Expanding access to priority health interventions: a framework for understanding the constraints to scaling-up. Journal of International Development 15: 1-14.
32. Frost LJ, Reich MR (2008) Access: How Do Good Health Technologies Get to Poor People in Poor Countries. Cambridge: Harvard Center for Population and Development Studies, distributed by Harvard University Press.
33. Drugs for Neglected Diseases Initiative (2012) Azoles E1224 & Biomarker (Chagas). Available: http://www.dndi.org/diseases-projects/portfolio/azoles-e1224.html. Accessed 16 September 2013.
34. Maxwell JA (2005) Qualitative Research Design: An Interactive Approach. Thousand Oaks, California: Sage Publications.
35. Fielding NG, Fielding JL (1986) Linking Data. Beverly Hills, California: Sage Publications.
36. Attaran A, (2006) Chagas' disease in Mexico. Lancet 368: 1768 discussion 1768-1769.
37. Kuri Morales P (2013) Follow-up to Ministers Leadership in Health Forum at Harvard. In: Michael Reich, editor. Mexico, D.F. pp. 1.
38. Direccion del Programa de Enfermedades Transmitidas por Vector (2011) Programa de Enfermedad de Chagas. Mexico City, DF: Subsecretaria de Prevencion y Promocion de la Salud- Centro Nacional de Programas Preventivos y Control de Enfermedades.
39. Moise P, Docteur E (2007) Pharmaceutical Pricing and Reimbursement Policies in Mexico. Paris, France: Organization for Economic Cooperation and Development.
40. Comision Federal Para la Proteccion Contra Riesgos Sanitarios (2010) Comprobante de Tramite (COFEPRIS-01-010-C). In: Secretaria de Salud, editor.
41. Comision Nacional de Proteccion Social en Salud/Seguro Popular (2012) Catalogo Universal de Servicios de Salud (CAUSES 2012). Mexico, DF: Comision Nacional de Proteccion Social en Salud.
42. Estados Unidos Mexicanos Secretaría de Salud (2002) Norma Oficial Mexicana para la vigilancia epidemiologica, prevencion, y control de enfermedades transmitidas por vector. In: Comité Consultivo Nacional de Normalización de Prevención y Control de Enfermedades, editor: Secretaria de Salud,.
43. Estados Unidos Mexicanos Secretaría de Salud (2010) Norma Oficial Mexicana para la vigilancia epidemiologica, prevencion y control de las enfermedades transmitidas por vector. Comité Consultivo Nacional de Normalización de Prevención y Control de Enfermedades.
44. Centro Nacional de Excelencia Technologica en Salud (2011) Guias de Practica Clinica. Secretaria de Salud de Mexico.
45. Medecins San Frontieres (2009) Patient Advocacy and Access to Care- Breaking Through the Barriers. Chagas Disease: Break the Silence, Time to Treat: Medecins San Frontieres.
46. Ramsey JM, Alvear AL, Ordonez R, Munoz G, Garcia A, et al. (2005) Risk factors associated with house infestation by the Chagas disease vector Triatoma pallidipennis in Cuernavaca metropolitan area, Mexico. Med Vet Entomol 19: 219-228.
47. Ramsey JM, (2005) La Enfermedad de Chagas en Oaxaca: Una estrategia educativa y eco-epidemiologia. Instituto Nacional de Salud Publica.
48. Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, et al. (2010) Tolerance and safety of nifurtimox in patients with chronic chagas disease. Clin Infect Dis 51: e69-75.
49. Guzman-Bracho C, (2001) Epidemiology of Chagas disease in Mexico: an update. Trends Parasitol 17: 372-376.
50. Ramsey JM (2007) Chagas disease Transmission in Mexico: A case for translational research, while waiting to take disease burden seriously. Cuernavaca, Mexico: Salud Publica de Mexico.
51. Guzman Bracho C, Garcia Garcia L, Floriani Verdugo J, Guerrero Martinez S, Torres Cosme M, et al. (1998) [Risk of transmission of Trypanosoma cruzi by blood transfusion in Mexico]. Rev Panam Salud Publica 4: 94-99.
52. Novelo-Garza BA, Benitez-Arvizu G, Pena-Benitez A, Galvan-Cervantes J, Morales-Rojas A, (2010) [Detection of Trypanosoma cruzi in blood donors]. Rev Med Inst Mex Seguro Soc 48: 139-144.
53. Moncayo A, Silveira AC, (2009) Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz 104 Suppl 1: 17-30.
54. Villar JC, (2001) Commentary: Control of Chagas' disease: let's put people before vectors. Int J Epidemiol 30: 894-895.
55. World Health Organization (2013) WHO Model List of Essential Medicines. 18th List ed: World Health Organization.
56. Hashimoto K, Kojima M, Nakagawa J, Yamagata Y, (2005) Effectiveness of Health Education through Primary School Teachers: Activities of Japan Overseas Cooperation Volunteers in the Control of Chagas' Disease Vectors in Guatemala. Technology and Development 18: 71-76.